This phase II study followed patients with ulcerative colitis and involved dose escalation, double-blind, and placebo aspects to test of the efficacy and safety of enema. Pharm-Olam was asked to rescue this study ongoing in France and Belgium. We recommended Poland to the sponsor and began regulatory submission promptly. Our goal was 20 patients in 12 weeks of enrollment with 5 sites. All patients were enrolled in just 8 weeks.